Orthofix Medical Beheer

Beheer criteriumcontroles 0/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Massimo Calafiore

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	less than a year
Eigendom CEO	0.08%
Management gemiddelde ambtstermijn	less than a year
Gemiddelde ambtstermijn bestuur	1.6yrs

Recente managementupdates

Recent updates

CEO

Massimo Calafiore (52 yo)

less than a year

Tenure

Mr. Massimo Calafiore is President, CEO & Director of Orthofix Medical Inc. from January 8, 2024 and as Interim President of Global Spine from January 10, 2024. Mr. Massimo Calafiore was the Chief Executiv...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Geoffrey Gillespie	VP & Corporate Controller	3.7yrs	US$887.05k	0.0088% € 59.3k
Massimo Calafiore	President	less than a year	geen gegevens	0.079% € 530.9k
Julie Andrews	Chief Financial Officer	less than a year	geen gegevens	geen gegevens
Aviva McPherron	President of Global Operations & Quality	less than a year	geen gegevens	geen gegevens
Julie Dewey	Chief Investor Relations & Communications Officer	less than a year	geen gegevens	geen gegevens
Jill Mason	Chief Compliance & Risk Officer	no data	geen gegevens	geen gegevens
J. Cedron	Chief Legal Officer & Corporate Secretary	less than a year	geen gegevens	geen gegevens
Stephanie Walsh	Chief Human Resources Officer	less than a year	geen gegevens	geen gegevens
Ehab Esmail	Senior Vice President of Global Quality	6yrs	geen gegevens	geen gegevens
Tyler Lipschultz	President of Global Biologics	2yrs	geen gegevens	geen gegevens
Beau Standish	President of Global Enabling Technologies	no data	geen gegevens	geen gegevens
Lucas Vitale	Chief People & Business Operations Officer	less than a year	geen gegevens	geen gegevens

0.9yrs

Gemiddelde duur

52yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van OM2 wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 0.9 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Massimo Calafiore	President	less than a year	geen gegevens	0.079% € 530.9k
John Henneman	Independent Director	2yrs	US$355.42k	0.090% € 607.0k
Alan Bazaar	Independent Director	1.1yrs	US$300.00k	0% € 0
Jason Hannon	Independent Director	4.6yrs	US$376.25k	0.012% € 80.7k
Charles Kummeth	Independent Director	1.1yrs	US$300.00k	0.039% € 264.6k
Michael Finegan	Independent Chair of the Board	1.1yrs	US$300.00k	0% € 0
Michael Paolucci	Independent Director	8.8yrs	US$376.25k	0.032% € 212.8k
Shweta Maniar	Independent Director	2yrs	US$355.42k	0.015% € 101.0k
Wayne Burris	Independent Director	1.6yrs	US$539.70k	0.017% € 112.6k

1.6yrs

Gemiddelde duur

60yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van OM2 wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.6 jaar), wat duidt op een nieuw bestuur.

Bedrijfsanalyse en status van financiële gegevens

Gegevens	Laatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse	2025/01/20 19:14
Aandelenkoers aan het einde van de dag	2025/01/17 00:00
Inkomsten	2024/09/30
Jaarlijkse inkomsten	2023/12/31

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

Pakket	Gegevens	Tijdframe	Voorbeeld Amerikaanse bron ^*
Financiële gegevens bedrijf	10 jaar	Resultatenrekening Kasstroomoverzicht Balans	SEC-formulier 10-K SEC-formulier 10-Q
Consensus schattingen analisten	+3 jaar	Financiële prognoses Koersdoelen analisten	Onderzoeksrapporten van analisten Blue Matrix
Marktprijzen	30 jaar	Aandelenprijzen Dividenden, splitsingen en acties	ICE Marktgegevens SEC-formulier S-1
Eigendom	10 jaar	Top aandeelhouders Handel met voorkennis	SEC-formulier 4 SEC-formulier 13D
Beheer	10 jaar	Leiderschapsteam Raad van bestuur	SEC-formulier 10-K SEC-formulier DEF 14A
Belangrijkste ontwikkelingen	10 jaar	Bedrijfsaankondigingen	SEC-formulier 8-K

^* voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige regelgevingsformulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Lees hier meer.

Analysemodel en Snowflake

Details van het analysemodel dat is gebruikt om dit rapport te genereren, zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen voor het gebruik van onze rapporten en tutorials op Youtube.

Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op .

Bronnen van analisten

Orthofix Medical Inc. wordt gevolgd door 19 analisten. 5 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

Analist	Instelling
Gregory Chodaczek	Boenning & Scattergood, Inc.
Michael Gorman	BTIG
William Plovanic	Canaccord Genuity

Orthofix Medical Beheer

Beheer criteriumcontroles 0/4

Belangrijke informatie

Recente managementupdates

Patrick Fisher Joins Orthofix as President of Global Orthopedics Business

Orthofix Names Stephanie Walsh as Chief Human Resources Officer

Orthofix Medical Inc. Appoints Michael Finegan as Chair of Board of Directors

Orthofix Medical Inc. Appoints Aviva Mcpherron as President of Global Operations and Quality

Orthofix Medical Inc. Appoints Max Reinhardt as President of Global Spine Business Effective June 10, 2024

Orthofix Medical Inc., Annual General Meeting, Jun 18, 2024

Recent updates

Third quarter 2024 earnings released: US$0.71 loss per share (vs US$0.78 loss in 3Q 2023)

Orthofix Medical Inc. Reiterates Earnings Guidance for Full Year 2024

Levi & Korsinsky, LLP Notifies Investors in Orthofix Medical Inc. of A Class Action Securities Law

Orthofix Medical Inc. to Report Q3, 2024 Results on Nov 07, 2024

Bronstein, Gewirtz & Grossman, LLC Files Lawsuit Against Orthofix Medical Inc. and Seaspine Holdings Corporation

No longer forecast to breakeven

Scott+Scott Attorneys At Law LLP Files Securities Class Action Lawsuit in the United States District Court for the Eastern District of Texas Against Orthofix Medical, Inc

Patrick Fisher Joins Orthofix as President of Global Orthopedics Business

New minor risk - Share price stability

Second quarter 2024 earnings released: US$0.88 loss per share (vs US$1.07 loss in 2Q 2023)

Orthofix Medical Inc. Revises Revenue Guidance for the Full Year 2024

Orthofix Names Stephanie Walsh as Chief Human Resources Officer

Orthofix Medical Inc. to Report Q2, 2024 Results on Aug 06, 2024

Orthofix Medical Inc. Announces First Implant of Fitbone Transport and Lengthening System

Orthofix Medical Inc.(NasdaqGS:OFIX) dropped from Russell 2000 Value-Defensive Index

Orthofix Medical Inc. Appoints Michael Finegan as Chair of Board of Directors

Orthofix Medical Inc. Appoints Aviva Mcpherron as President of Global Operations and Quality

Orthofix Medical Inc. Appoints Max Reinhardt as President of Global Spine Business Effective June 10, 2024

Orthofix Medical Inc. Announces FDA 510(K) Clearance for the Rodeo Telescopic Nail

Orthofix Medical Inc. Revises Earnings Guidance for the Year 2024

First quarter 2024 earnings released: US$0.95 loss per share (vs US$1.71 loss in 1Q 2023)

Orthofix Medical Inc., Annual General Meeting, Jun 18, 2024

Orthofix Medical Inc. to Report Q1, 2024 Results on May 07, 2024

Orthofix Medical Inc. Appoints Andres Cedron as New Chief Legal Officer

New minor risk - Profitability

Orthofix Medical Inc. Announces Board Resignation

Orthofix Medical Inc. Appoints Lucas Vitale as Chief People and Business Operations Officer

Full year 2023 earnings released: US$4.12 loss per share (vs US$0.98 loss in FY 2022)

Orthofix Medical Inc. Provides Earnings Guidance for the Year 2024

Orthofix Medical Inc. to Report Q4, 2023 Results on Mar 05, 2024

Orthofix Medical Inc. Names Massimo Calafiore as President and Member of the Board of Directors Effective Immediately

Orthofix Medical Inc. Appoints Julie Andrews as Chief Financial Officer

Orthofix Announces Publication of New Data Supporting Use of PEMF Stimulation in Lumbar Spine Fusion Procedures for Patients at Risk of Pseudarthrosis

Orthofix Medical Inc. Announces Board Changes

Orthofix Medical Inc. Appoints Massimo Calafiore as Chief Executive Officer, Effective in Early 2024

Orthofix Medical Inc. Revises Earnings Guidance for the Year Ending December 31, 2023

Third quarter 2023 earnings released: US$0.78 loss per share (vs US$0.53 loss in 3Q 2022)

Orthofix Medical Inc. Announces Full Commercial Launch of the Waveform L Interbody System for Lateral Lumbar Fusion Procedures

Orthofix Medical Inc. to Report Q3, 2023 Results on Nov 08, 2023

Orthofix Medical Inc. Announces 510k Clearance and Full Commercial Launch of OsteoCove, an Advanced Bioactive Synthetic Graft for Use in Spine and Orthopedic Procedures

Orthofix Medical Inc. Announces First Patient Procedures and Full Commercial Launch of the Galaxy Fixation Gemini System and Expanded Sterile Kit Offerings for Orthopedic Trauma Procedures

Independent Director recently bought €95k worth of stock

Orthofix Medical Inc. Announces Management Appointments

Orthofix Medical Inc. Announces Management Changes

Second quarter 2023 earnings released: US$1.07 loss per share (vs US$0.12 profit in 2Q 2022)

Orthofix Medical Inc. Revises Earnings Guidance for the Year Ending December 31, 2023

Orthofix Medical Inc. to Report Q2, 2023 Results on Aug 08, 2023

Orthofix Medical Inc. Introduces New Phantom and Tornado Hins for Truelok Ring Fixation Systems

Orthofix Medical Inc. Announces Changes to Board of Directors

Orthofix Medical Inc Announces the Full Commercial Launch of WaveForm A 3D Printed Anterior Lumbar Interbody

Orthofix Medical Inc. Announces First Presentation of Seven-Year Outcome Data for the M6-C Artificial Cervical Disc with Other Clinical and Scientific Abstracts At the Isass Annual Meeting

President of Global Spine Business recently sold €146k worth of stock

First quarter 2023 earnings released: US$1.71 loss per share (vs US$0.22 loss in 1Q 2022)

Orthofix Medical Inc. Revises Sales Guidance for the Year 2023

Full year 2022 earnings released: US$0.98 loss per share (vs US$1.95 loss in FY 2021)

High number of new directors

Orthofix Announces Full Commercial Launch and First Patient Cases of Mariner Deformity System

Orthofix Medical Inc. Provides Unaudited Preliminary Net Sales Results Fourth Quarter and Full Year Ended December 31, 2022

Orthofix Medical Inc. Announces CFO Changes

Orthofix Medical Inc. Announces Publication of Data Demonstrating the Clinical Benefits of Trinity Elite Cellular Bone Allograft in Lumbar Fusion Procedures

Two unknown private equity fund sponsors submitted a non-binding indication of interest to acquire Orthofix Medical Inc. (NasdaqGS:OFIX) for approximately $460 million.

Orthofix and SeaSpine Announce John Bostjancic to Serve as CFO for Combined Company Post Closing

High number of new directors

Third quarter 2022 earnings released

Orthofix Medical Inc. Provides Financial Guidance for the Full Year 2022

Orthofix Medical Inc. to Report Q3, 2022 Results on Nov 03, 2022

Orthofix Announces First Patient Implants with Legacy Demineralized Bone Matrix for Spine, Pelvic and Extremities Procedures

Orthofix Medical Inc. (NasdaqGS:OFIX) entered into a definitive agreement to acquire SeaSpine Holdings Corporation (NasdaqGS:SPNE) for approximately $280 million in a merger of equals transaction.

Orthofix Medical Inc. (NasdaqGS:OFIX) entered into a definitive agreement to acquire SeaSpine Holdings Corporation (NasdaqGS:SPNE) for approximately $280 million in a merger of equals transaction.